Drug intelligence / Profile preview

anti-syndecan-2 antibody

Development stage: Preclinical
Lead developer: VST Bio
Modality: Antibody-Based Therapeutics
Administration: Ophthalmic, Intravenous

Overview

Anti-syndecan-2 antibody is a polyclonal antibody biologic targeting syndecan-2 (Sdc2), a heparan sulfate proteoglycan transmembrane protein. It is being developed as a therapeutic approach for retinal vascular diseases, such as wet age-related macular degeneration (AMD), and myocardial infarction (MI) complications. The antibody specifically blocks VEGF-A-induced vascular permeability and edema formation without interfering with other VEGF-A signaling pathways, potentially offering a safer alternative to traditional anti-VEGF therapies. Development involves VST Bio in collaboration with Yale University and Karolinska Institutet.

Other names: anti-Sdc2 antibodyanti-Sdc-2 antibodyanti-Sdc 2 antibody

Targets

SDC2 (Syndecan-2)

Beyond the preview

Go deeper on anti-syndecan-2 antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-syndecan-2 antibody.

Explore the full profile